The rates of the breast cancer subtypes were luminal A-like in 14.6% of patients, luminal B-like in 47.2%, HR+/HER2+ in 7.3%, HR−/HER2+ in 7.0%, triple negative in 17.1%, and of unknown subtype in 6.7%. This evidence concerns the gene ERBB2 and breast carcinoma.